Print version ISSN 1516-4446
Rev. Bras. Psiquiatr. vol.27 no.3 São Paulo Sept. 2005
Moduladores de glutamato como novas intervenções em transtornos do humor
Sanjay J Mathew; Kathryn Keegan; Lisa Smith
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY
Recent evidence suggests that critical molecules in neurotrophic signaling cascades are long-term targets for currently available monoaminergic antidepressants. As chronic and severe mood disorders are characterized by impairments in neuronal resilience, pharmacological strategies that subserve a neuroprotective function might alter disorder pathophysiology and modify disease progression. Several promising approaches involve modulation of the glutamate neurotransmitter system, via post-synaptic receptor blockade or potentiation and presynaptic vesicular release inhibition. A focused review of the extant scientific literature was conducted, with a discussion of 3 compounds or classes of drugs currently undergoing clinical investigation: ketamine, riluzole, and AMPA receptor potentiators. Recent investigations in mood disordered patients suggest that the NMDA receptor antagonist ketamine might demonstrate rapid antidepressant properties. Riluzole has been shown to reverse glutamate-mediated impairments in neuronal plasticity and to stimulate the synthesis of brain derived neurotrophic factor. Open-label trials in treatment-resistant depression have yielded promising results. Likewise, AMPA receptor potentiators favorably impact neurotrophic factors as well as enhance cognition.
CONCLUSIONS: Pharmacological approaches that modulate components of the glutamate system offer novel targets for severe, recurrent mood disorders. Controlled studies are necessary.
Keywords: Mood disorders/drug therapy; Signal transduction/drug effects; Antidepressive agents/therapeutic use; Glutamates/therapeutic use; Ketamine/therapeutic use; Riluzole/therapeutic use; Receptors, AMPA;
Recentes evidências sugerem que as moléculas críticas nas cascatas de sinalização neurotrófica são alvos de longo prazo dos antidepressivos monoaminérgicos disponíveis atualmente. Na medida em que transtornos graves e crônicos são caracterizados por deficiências na resiliência neuronal, estratégias farmacológicas que sejam úteis para uma função neuroprotetora talvez possam alterar a fisiopatologia e modificar a progressão da doença. Vários enfoques promissores envolvem a modulação do sistema neurotransmissor do glutamato, via bloqueio ou potencialização do receptor pós-sináptico e inibição da liberação vesicular pré-sináptica. Foi realizada uma revisão focada da literatura científica existente, com a discussão de três compostos ou classes de drogas que estão atualmente sob investigação clínica: a ketamina, o riluzol e os potencializadores de receptores de AMPA.
DISCUSSÃO: Estudos recentes com pacientes com transtornos de humor sugerem que a ketamina, um antagonista do receptor NMDA, poderia ter demonstrado propriedades antidepressivas rápidas. O riluzol demonstrou reverter deficiências mediadas pelo glutamato na plasticidade neuronal e estimular a síntese de fatores neurotróficos derivados do cérebro. Ensaios abertos com depressão resistente ao tratamento produziram resultados promissores. Da mesma forma, os potencializadores de receptores de AMPA impactam favoravelmente os fatores neurotróficos, assim como melhoram a cognição.
CONCLUSÕES: Enfoques farmacológicos que modulam os componentes do sistema de glutamato oferecem novos alvos para transtornos de humor recorrentes e graves. São necessários estudos controlados.
Descritores: Transtornos do humor/quimioterapia; Transdução de sinal/efeitos de droga; Antidepressivos/uso terapêutico; Glutamatos/uso terapêutico; Ketamina/uso terapêutico; Riluzol/uso terapêutico; Receptores de AMPA
1. Pathophysiological models of mood disorders emphasize impairments in cellular plasticity
Current pathophysiological theories regarding the neurobiology of mood disorders, including major depression and bipolar disorder, include alterations in intracellular signaling cascades and impairments of cellular plasticity and resilience.1-3 There is recent evidence suggesting that critical molecules in neurotrophic signaling cascades such as brain derived neurotrophic factor (BDNF) and mitogen activated protein (MAP) kinases are long-term targets for currently available antidepressants, such as the selective serotonin reuptake inhibitors (SSRIs). New data indicating modulation of specific glutamate receptors as a key component of the mechanism of action of conventional antidepressants suggests an approach to develop a novel class of antidepressants that enhances neuronal plasticity and cellular resilience.2 One of the underlying themes guiding this work is that agents that enhance cellular plasticity and resilience, rather than solely functioning in limited neurogenesis models, might have particular salience for the treatment of severe, recurrent, difficult-to-treat mood disorders.1 Thus, the unifying hypothesis of this pharmacological approach is that new treatments for mood disorders, in addition to attenuating the constellation of symptoms that manifest as the complex syndrome of depression (e.g. anergia, hopelessness, insomnia or hypersomnia, suicidal thoughts, anhedonia), would also reverse impairments of cellular resilience, reductions in brain volume, and regional glial and neuronal cell death.
An increasing number of neuroimaging, neuropathological, and biochemical studies consistently suggest that impairments in neuroplasticity and cellular resilience are found in patients who suffer from severe, recurrent mood disorders. Recent morphometric magnetic resonance imaging (MRI) and post-mortem investigations have demonstrated abnormalities of brain structure that correspond to abnormalities of metabolic activity.4-5 Structural imaging studies demonstrate reduced gray matter volumes in areas of the orbital and medial pre-frontal cortex (PFC), temporal lobe, and enlargement of the third ventricle in patients with mood disorders compared to healthy controls (reviewed in6-7). Recent post-mortem neuropathological studies in mood disorder patients are complementary, showing reductions in cortical volume and region- and layer-specific reductions in number, density, and/or size of neurons and glial cells in the subgenual PFC, orbital cortex, dorsal anterolateral PFC, amygdala, and basal ganglia and dorsal raphe nuclei (reviewed in4,8). It is important to note, however, that it is not known what the above-noted structural and functional alterations constitute: 1) developmental abnormalities conferring vulnerability to severe mood episodes; 2) compensatory changes to other pathogenic processes; 3) sequelae of recurrent affective episodes; 4) effects of comorbidity or pharmacological treatments; or 5) epiphenoma which lack significance for the clinical phenotype of the disorder. Understanding these issues will partly depend upon experiments that delineate the onset of such abnormalities within the illness course and determine if they antedate mood episodes in high-risk individuals.
We conducted a selective literature review of several promising classes of agents that impact the glutamate system. This article reviews the mechanisms and clinical profile of three candidate compounds undergoing large-scale studies in the United States: ketamine, riluzole, and AMPA receptor potentiators, or AMPAkines.
1. Overview of the glutamate system
Glutamate is the major excitatory synaptic neurotransmitter in the brain and plays a vital role in the regulation of several important CNS processes, including the regulation of synaptic plasticity, learning, and memory.9-12 Glutamate is found in greater than 80% of neurons and exists in relatively high concentrations in brain tissue (approximately 8-10 mmol/kg, in contrast to monoamines, which are in the µmol/kg range). Because of the putative role of glutamate in neuronal plasticity and its relative ubiquity, modulation of the glutamatergic system is being investigated in several ongoing clinical studies in neuropsychiatric disorders marked by impairments in mood, concentration, attention, and memory.13
Glutamate exerts its action at the presynaptic and postsynaptic level through the stimulation of specific receptors that can be classified by structural characteristics; the first group, "ionotropic glutamate receptors", which include N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainate families of receptors, are ion channels, which when stimulated open the channel pore allowing sodium, potassium or calcium to flow freely into the cell. This opening of the pore changes the polarization of the neuronal surface and often activates intracellular signaling pathways. AMPA receptors mediate the majority of excitatory synaptic transmission in the CNS, and the AMPA R channels are comprised of four subunits (GluR1, GluR2, GluR3, and GluR4). The second group, "metabotropic receptors" are G-protein-coupled receptors that exert their actions through second messenger pathways. Therapeutic agents, such as the mGlu receptor agonists, can specifically target these receptors; it is also possible to target the release of glutamate before it binds to either the ionotropic or metabotropic receptors. The most recently described pharmacological target in the glutamate system is the family of excitatory amino acid transporters (EAATs), which serve to remove glutamate from the synapse. Subtypes 1 and 2 in particular, which are localized to astrocytes, appear to play a major role in glutamate reuptake and subsequent conversion into glutamine. Recent groundbreaking work from Johns Hopkins has found that specific classes of antibiotics increase gene expression of subtypes of EAATs, offering a novel mechanism for modulation of synaptic glutamate concentrations and resultant glutamate excitoxicity. Thus, therapeutic agents directed at these different molecular glutamatergic targets may result in complex effects on a wide range of neuropsychiatric symptoms.2
Candidate drugs impacting primarily on glutamate receptors include the following: NMDA receptor antagonists, metabotropic glutamate receptor (mGluR) agonists and antagonists, and positive modulators of AMPA receptors. These candidate molecules have demonstrated antidepressant-like properties in preclinical and clinical studies.3,14-15 For NMDA antagonists in particular, there is now substantial preclinical evidence that these agents have antidepressant properties. Chronic treatment with NMDA antagonists resulted in antidepressant-like behavioral effects in models such as chronic mild stress, learned helplessness, footshock-induced aggression, and olfactory bulbectomy (reviewed in14). Chronic, but not acute treatment with NMDA antagonists also resulted in reductions in density of forebrain b-adrenoreceptors16-17 and 5-HT2 receptors.18 In a fashion similar to that of monoamine-based antidepressants, NMDA antagonists given to animals processed in the forced swim test resulted in a rapid down-regulation of forebrain b-adrenoceptors.19 Finally, repeated administration of conventional antidepressants has been found to alter the expression of mRNA that encodes NMDA receptor subunits,20 through expression of BDNF.21
Perhaps the most robust clinical evidence that modulation of glutamatergic activity may be important in the treatment of mood disorders comes from the extensive clinical utility of the anticonvulsant lamotrigine.22-23 Many clinicians believe lamotrigine to be particularly effective for treatment resistant mood disorders, and its utility in the depressed phase of bipolar disorder is now well established. While lamotrigine has multiple cellular effects, including inhibition of use-dependent sodium and P-and N-type calcium channels, inhibition of an excessive release of glutamate appears to be an important aspect of its mechanism of action.24-26 In healthy volunteers given ketamine, an NMDA antagonist, investigators at Yale reported that lamotrigine attenuated the hyperglutamatergic consequences of NMDA receptor dysfunction, namely the cognitive dysfunction and psychomimetic effects of ketamine.27
The remaining sections of this paper will discuss 3 drugs (or drug classes) that impact varied components of the glutamate system: ketamine, riluzole, and AMPA receptor potentiators. Based on promising proof-of-concept pilot trials with small sample sizes, these compounds are being actively studied in larger samples for treatment-resistant mood disorders in several centers in the United States.
2. The ketamine model for rapid mood elevation
Existing treatments for depression may take several weeks to months to exhibit an antidepressant effect. Given the increased morbidity and mortality resulting from failure to treat depression in a timely fashion, there is clearly a need to develop rapidly-acting and potent treatments in addition to electroconvulsive therapy (ECT), which is generally considered to be the most rapid and potent form of treatment. Ketamine, a high-affinity non-competitive NMDA antagonist, has been used as a standard anesthetic agent for many years in both pediatrics and adults, with doses as high as 2 mg/kg.
There is abundant preliminary evidence that ketamine has anxiolytic and antidepressant effects in animal models28-31 and may have rapid antidepressant properties. The Yale group reported the first placebo-controlled, double-blind trial investigating the effects of a single dose of intravenous ketamine (0.5 mg/kg) in 9 patients with depression,32 work recently replicated in a larger sample at NIMH. In the Yale report, investigators32 administered either the noncompetitive NMDA antagonist ketamine or saline to patients who were unresponsive to conventional antidepressants. Ketamine (0.5 mg/kg, infused over 40 minutes) significantly reduced depression rating scales scores within 3 hours. The reduction in depression scores continued to emerge over time, and persisted beyond 72 hours, the planned duration of the study. At the point the study was terminated (72 hours), the Hamilton scores were significantly reduced (Mean ± SD) 14 ± 10 and 0 ± 12 points in the ketamine and saline conditions, respectively. All subjects relapsed and were within 5 points of their baseline Hamilton scores before the end of the week.
Studies with NMDA antagonists (e.g., ketamine) and other glutamate modulators have been conducted for many years in healthy controls, in patients with schizophrenia, in substance abusers and in patients with major depression in an attempt to better understand the role of the glutamatergic system in neuropsychiatric disorders.33-34 Since NMDA receptor modulation has a powerful, albeit complex, effect on biogenic amine turnover, it could be argued that the antidepressant-like actions of functional NMDA antagonists result from elevated levels of biogenic amines (e.g., norepinephrine and dopamine). However, the rapid antidepressant action of ketamine32 indicates that it is the NMDA antagonist properties per se that are responsible for these effects since intravenous infusion of biogenic-amine based agents (e.g., an SSRI or tricyclic) will not produce such a rapid improvement in symptoms. However, while study findings are encouraging,32 it is important to note that this was a serendipitous finding and was not the primary aim of the study. In addition, the study sample size was small. Thus, larger controlled studies are necessary to adequately test this intriguing pilot finding.
3. Enhancement of neuroplasticity: the example of riluzole
A significant challenge for depression research is identifying optimal continuation therapy for the prevention of relapse following acute remission of symptoms.35 As discussed, lamotrigine was found to increase the immediate mood-elevating effects of ketamine in healthy volunteers.27 An important unanswered question is the relationship between a drug's ability to potentiate the acute response to ketamine and its ability to prevent relapse of symptoms following effective treatment with ketamine. Could an anti-glutamatergic drug with a similar mechanism of action to lamotrigine be effective for continuation therapy for patients who acutely respond to ketamine? Recent investigations suggest that the glutamate antagonist riluzole, the only U.S. FDA-approved drug for amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease), impacts numerous neurochemical and neuropeptide systems relevant to mood disorders. A recent open-label trial showed significant antidepressant effects of riluzole in nineteen treatment-resistant patients with unipolar depression.36 Patients showed significant improvement on the MADRS scale for depression and concurrent reductions in comorbid anxiety symptoms (shown by reductions in Hamilton Anxiety Rating score). Riluzole was also beneficial for patients with bipolar depression as an augmenting agent to lithium.37 In these studies, all patients who responded were remitters, suggesting a subgroup of mood disorder patients who might be particularly appropriate for this intervention. Although the mechanisms of lamotrigine and riluzole appear to be similar, preliminary data from NIMH has also found that patients who had previously failed to respond to lamotrigine subsequently responded to riluzole.
Chemically, riluzole is 2-amino-6- trifluoromethoxybenzothiazole,38 and easily penetrates the blood-brain barrier.39 Evidence from a variety of studies with experimental animals and with humans indicates that riluzole is devoid of the psychotomimetic or other behavioral side-effects commonly associated with excitatory amino acid antagonists.40-41
In contrast to several glutamate modulating drugs (memantine, ketamine), riluzole does not appear to act directly on the NMDA receptor.42 Rather, the mechanism of its anti-glutamatergic (and antiepileptic) effect is through the (1) inhibition of voltage-dependent sodium channels in mammalian CNS neurons43-44 and the (2) inhibition of glutamate release.45 However, tetrodotoxin, a sodium channel blocking agent, failed to block the inhibitory effect of riluzole on glutamate, suggesting that the effects of riluzole are not exclusively mediated by its action on sodium channels.46 The anticonvulsant activity of riluzole may also be due to its effect on neurotransmission mediated by the (3) AMPA/KA receptors,42,47-50 however, the mechanism by which riluzole interacts with these receptors in brain and spinal motor neurons remains unclear.51 There is also evidence that riluzole inhibits presynaptic glutamate release through (4) inactivation of P/Q-type calcium channels.52 This release inhibition may involve a pertussis toxin-sensitive G protein signaling pathway. Recently, we and others have reported riluzole's efficacy in patients with primary anxiety disorders (Mathew et al, in press) and in anxiety associated with MDD.36 One intriguing mechanism that could explain these findings is evidence that at higher concentrations riluzole strongly (5) potentiated postsynaptic GABAA receptor function in cultured hippocampal neurons.53 Commonly used anxiolytics such as benzodiazepines bind to and allosterically interact with GABAA receptors, which mediate most fast inhibitory neurotransmission in the CNS. Finally, and perhaps most exciting given recent pathophysiological hypotheses regarding mood disorders,15 a recent report has suggested that riluzole (6) enhances glutamate uptake in rat astrocyte cultures.54 By acting directly on astrocytic glutamate transporters at low riluzole concentrations, there was a significant increase in the rate of glutamate uptake by astrocytes, which quantitatively are the most important regulators of normal extracellular glutamate concentrations.55-56 Thus, riluzole appears to confer neuroprotection and anticonvulsant activity through numerous mechanisms (Table 1).
Our pilot studies found that 8 weeks of open-label riluzole treatment was effective in 18 patients with generalized anxiety disorder, of whom half had histories of dysthymia or MDD (Mathew et al, in press). Using 1H-MRS in the same sample, we also found that riluzole reversed glutamate-mediated impairments in neuronal plasticity by increasing N-acetyl-aspartate (NAA), a neuronal marker, in the left hippocampus. These neuroimaging findings are potentially consistent with preclinical reports of riluzole stimulation of brain derived neurotrophic factor (BDNF) synthesis in cultured mouse astrocytes.
Thus, riluzole might fundamentally alter disorder pathophysiology by enhancing neuronal resilience and plasticity. Inasmuch as a growing body of data suggests that mood and anxiety disorders are also associated with regional volumetric reductions, cell loss, and atrophy,6 we have hypothesized that riluzole would be efficacious for mood disorders (and associated anxiety symptoms) due to reduced glutamate excitotoxicity and reversal of impairments in neurotrophic markers.57
4. Beyond NMDA: renewed interest in AMPA receptor potentiators
We have already seen that by increasing synaptic non-NMDA glutamatergic neurotransmission, as is the case with ketamine, rapid antidepressant effects are possible. AMPA receptors, which like NMDA receptors are involved in learning and memory, mediate the fast component of excitatory neurotransmission, and AMPA potentiation may result in rapid as well as subacute antidepressant efficacy. Several classes of compounds can allosterically modulate AMPA receptors. These compounds (so-called AMPA receptor positive modulators or AMPA receptor potentiators, ARPs) do not activate AMPA receptors themselves but slow the rate of receptor desensitization and/or deactivation in the presence of an agonist (e.g., glutamate and AMPA).58-59 AMPAkines, a subclass of ARPs, are small benzamide compounds that allosterically produce positive modulation of AMPA receptors. Clinically, this drug class has been studied as add-on treatment to clozapine in patients with schizophrenia,60 with consistent patterns of improvement in performance on tests of attention, memory, and distractibility. Preclinical work has shown that the biarylpropylsulfonamide AMPA receptor potentiators (LY392098 and LY451616) have antidepressant effects in animal models of depression (including the application of inescapable stressors, forced-swim test, and tail-suspension-induced immobility tests), in learned-helplessness models of depression, and in animals exposed to chronic mild stress.61 In one of these pre-clinical studies, the AMPAkine Ampalex was reported to have more rapid effects (during the first week of treatment) than fluoxetine (after 2 weeks).62
There is also evidence that AMPA receptors appear responsive to chronic antidepressant treatment, consistent with neural adaptative mechanisms believed to underlie the therapeutic response to these treatments.14 One group has reported that chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus.63 In addition, chronic treatment with fluoxetine increased phosphorylation of the Ser831-GluR1 and Ser845-GluR1 sites of AMPA receptor in extracts of cortex, hippocampus, and striatum.64 In contrast to traditional antidepressants, this group of compounds does not appear to affect the extracellular concentration of monoamines.65 However, several studies have demonstrated that AMPA receptor activation can increase expression of BDNF both in vitro and in vivo.66-68 In addition, LY392098, an AMPA receptor potentiator, increased BDNF mRNA in primary neuronal culture.69
Modulation of neurotrophic factor expression and alteration of the rate of neurogenesis may be critical factors that contribute to the understanding of the therapeutic effects of antidepressants and mood stabilizers in mood disorders.1 In support of this notion, chronic treatment with the AMPA receptor potentiator LY451646 increased progenitor cell proliferation in the dentate gyrus in a dose-dependent manner. The antidepressant-like activity of ARPs in animals may be attributed, at least in part, to the regulation of cell proliferation in the hippocampus.70 In summary, abundant preclinical evidence exists in support of AMPA receptor potentiation as a potential therapy for mood disorders. Based on these data, ongoing trials of novel AMPA receptor potentiators in severe mood disorders are underway.
While the focus of this review has concerned the mood-enhancing aspects of glutamatergic drugs, it should be noted that enhancement of cognitive function is an important additional goal of antidepressant treatment. In that respect, the approaches described, particularly AMPA receptor potentiators, have promise in this area. It is well recognized that significant neuropsychological deficits occur in chronic mood disorders, including alterations in memory, attention, and executive functioning.
The question has been raised: Does allosteric modulation of AMPA receptors promote long-term changes in glutamatergic synaptic signaling and thereby facilitate memory encoding?71 In humans, early studies showed that administration of pyrrolidinones, a class of AMPA receptor potentiator, improved cognition function in patients with schizophrenia and Parkinson's disease.72-73 Studies with benzyolgpiperdines, another class of AMPA receptor potentiator, have shown enhanced recall in healthy subjects.74 Clearly, the next step is to test these compounds in patients with mood disorders, with assessment of cognition after treatment.
Significant advances in psychopharmacology have been limited in the last few decades, likely due to poor understanding of the disease biology. It remains to be determined whether all patients with mood disorders will benefit from these glutamate-based approaches, or rather, only a selected subgroup. Identifying predictors of pharmacological response remains an important and active area of research, and tools from brain imaging and genetics will enable enhanced precision in identifying suitable candidate drugs for the individual patient with depression.
Supported by NIMH Career Development Award K23MH069656. We thank Dennis Charney, M.D., Kirk Denicoff, M.D., Jack M. Gorman, M.D., Husseini Manji, M.D., Gerard Sanacora, M.D., and Carlos Zarate, M.D. for their valuable contributions.
1. Charney DS, Manji HK. Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE. 2004;2004(225):re5. [ Links ]
2. Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, Gray NA, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry. 2003;53(8):707-42. [ Links ]
3. Zarate CA Jr, Du J, Quiroz J, Gray NA, Denicoff KD, Singh J, et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann NY Acad Sci. 2003;1003:273-91. [ Links ]
4. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med. 2001;7(5):541-7. [ Links ]
5. Drevets WC. Neuroimaging abnormalities in the amygdala in mood disorders. Ann N Y Acad Sci. 2003;985:420-44. [ Links ]
6. Drevets WC. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol. 2001;11(2):240-9. [ Links ]
7. Beyer JL, Krishnan KR. Volumetric brain imaging findings in mood disorders. Bipolar Disord. 2002;4(2): 89-104. [ Links ]
8. Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry. 2001;58(6):545-53. [ Links ]
9. Bannerman DM, Good MA, Butcher SP, Ramsay M, Morris R. Distinct components of spatial learning revealed by prior training and NMDA receptor blockade. Nature. 1995;378(6553):182-6. [ Links ]
10. Collingridge GL. Long-term potentiation. A question of reliability. Nature. 1994;371(6499):652-3. [ Links ]
11. Collingridge GL, Bliss TV. Memories of NMDA receptors and LTP. Trends Neurosci. 1995;18(2):54-6. [ Links ]
12. Watkins J, Collingridge G. Phenylglycine derivatives as antagonists of metabotropic glutamate receptors. Trends Pharmacol Sci. 1994;15(9):333-42. [ Links ]
13. Zarate CA, Quiroz J, Payne J, Manji HK. Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull. 2002;36(4):35-83. [ Links ]
14. Paul IA, Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci. 2003;1003:250-72. [ Links ]
15. Sanacora G, Rothman DL, Mason GF, Krystal JH. Clinical studies implicating glutamate neurotransmission in mood disorders. Ann NY Acad Sci. 2003;1003:292-308. [ Links ]
16. Paul IA, Trullas R, Skolnick P, Nowak G. Down-regulation of cortical beta-adrenoceptors by chronic treatment with functional NMDA antagonists. Psychopharmacology (Berl). 1992;106(2):285-7. [ Links ]
17. Maj J, Klimek V, Golembiowska K, Rogoz Z, Skuza G. Central effects of repeated treatment with CGP 37849, a competitive NMDA receptor antagonist with potential antidepressant activity. Pol J Pharmacol. 1993;45(5-6):455-66. [ Links ]
18. Papp M, Klimek V, Willner P. Effects of imipramine on serotonergic and beta-adrenergic receptor binding in a realistic animal model of depression. Psychopharmacology (Berl). 1994;114(2):309-14. [ Links ]
19. Wedzony K, Klimek V, Nowak G. Rapid down-regulation of beta-adrenergic receptors evoked by combined forced swimming test and CGP 37849a competitive antagonist of NMDA receptors. Pol J Pharmacol. 1995;47(6):537-40. [ Links ]
20. Boyer PA, Skolnick P, Fossom LH. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. J Mol Neurosci. 1998;10(3):219-33. [ Links ]
21. Brandoli C, Sanna A, De Bernardi MA, Follesa P, Brooker G, Mocchetti I. Brain-derived neurotrophic factor and basic fibroblast growth factor downregulate NMDA receptor function in cerebellar granule cells. J Neurosci. 1998;18(19):7953-61. [ Links ]
22. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999;60(2):79-88. [ Links ]
23. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20(6):607-14. [ Links ]
24. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia. 1986;27(5):490-7. [ Links ]
25. Calabresi P, Siniscalchi A, Pisani A, Stefani A, Mercuri NB, Bernardi G. A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices. Neurology. 1996;47(2):557-62. [ Links ]
26. Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW. Presynaptic inhibition of excitatory neurotransmission by lamotrigine in the rat amygdalar neurons. Synapse. 1996;24(3):248-55. [ Links ]
27. Anand A, Charney, DS, Oren DA, Berman RM, Hu XS, Cappiello A, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry. 2000;57(3):270-6. [ Links ]
28. Adamec RE, Burton P, Shallow T, Budgell J. Unilateral block of NMDA receptors in the amygdala prevents predator stress-induced lasting increases in anxiety-like behavior and unconditioned startleeffective hemisphere depends on the behavior. Physiol Behav. 1999;65(4-5):739-51. [ Links ]
29. Aguado L, San Antonio A, Perez L, del Valle R, Gomez J. Effects of the NMDA receptor antagonist ketamine on flavor memory: conditioned aversion, latent inhibition, and habituation of neophobia. Behav Neural Biol. 1994;61(3):271-81. [ Links ]
30. Mickley GA, Schaldach MA, Snyder KJ, Balogh SA, Len T, Neimanis K, et al. Ketamine blocks a conditioned taste aversion (CTA) in neonatal rats. Physiol Behav. 1998;64(3):381-90. [ Links ]
31. Silvestre JS, Nadal R, Pallares M, Ferre N. Acute effects of ketamine in the holeboard, the elevated-plus maze, and the social interaction test in Wistar rats. Depress Anxiety. 1997;5(1):29-33. [ Links ]
32. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-4. [ Links ]
33. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl). 2003;169(3-4):215-33. [ Links ]
34. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry. 2004;9(11):984-97, 979. [ Links ]
35. Sackeim HA, Rush AJ, George MS, Marangell LB, Husain MM, Nahas Z, et al. Vagus Nerve Stimulation (VNSTM) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001;25(5):713-28. [ Links ]
36. Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, et al. An open label trial of riluzole in patients with treatment resistant major depression. Am J Psychiatry. 2004;161(1):171-4. [ Links ]
37. Zarate CA, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57(4):430-2. [ Links ]
38. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330(9):585-91. [ Links ]
39. Benavides J, Camelin JC, Mitrani N, Flamand F, Uzan A, Legrand JJ, et al. 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmissionII: Biochemical properties. Neuropharmacology. 1985;24(8):1085-92. [ Links ]
40. Kretschmer BD, Kratzer U, Schmidt WJ. Riluzole, a glutamate release inhibitor, and motor behavior. Naunyn Schmiedebergs Arch Pharmacol. 1998;358(2):181-90. [ Links ]
41. Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996;47(6 Suppl 4):S233-41. [ Links ]
42. Debono MW, Le Guern J, Canton T, Doble A, Pradier L. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol. 1993;235(2-3):283-9. [ Links ]
43. Urbani A, Belluzzi O. Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci. 2000;12(10):3567-74. [ Links ]
44. Benoit E, Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflugers Arch. 1991;419(6):603-9. [ Links ]
45. Cheramy A, Barbeito L, Godeheu G, Glowinski J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett. 1992;147(2):209-12. [ Links ]
46. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol. 1993;250(3):473-6. [ Links ]
47. Siniscalchi A, Bonci A, Mercuri NB, Bernardi G. Effects of riluzole on rat cortical neurones: an in vitro electrophysiological study. Br J Pharmacol. 1997;120(2):225-30. [ Links ]
48. De Sarro G, Siniscalchi A, Ferreri G, Gallelli L, De Sarro A. NMDA and AMPA/kainate receptors are involved in the anticonvulsant activity of riluzole in DBA/2 mice. Eur J Pharmacol. 2000;408(1):25-34. [ Links ]
49. Hubert JP, Burgevin MC, Terro F, Hugon J, Doble A. Effects of depolarizing stimuli on calcium homeostatis in cultured rat motoneurones. Br J Pharmacol. 1998:125(7):1421-8. [ Links ]
50. Keita H, Lepouse C, Henzel D, Desmonts JM, Mantz J. Riluzole blocks dopamine release evoked by N-methyl-D-aspartate, kainate, and veratridine in the rat striatum. Anesthesiology. 1997;87(5):1164-71. [ Links ]
51. Albo F, Pieri M, Zona C. Modulation of AMPA receptors in spinal motor neurons by the neuroprotective agent riluzole. J Neurosci Res. 2004;78(2):200-7. [ Links ]
52. Wang SJ, Wang KY, Wang WC. Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 2004;125(1):191-201. [ Links ]
53. He Y, Benz A, Fu T, Wang M, Covey DF, Zorumski CF, et al. Neuroprotective agent riluzole potentiates postsynaptic GABAA receptor function. Neuropharmacology. 2002;42(2):199-209. [ Links ]
54. Frizzo ME, Dall'Onder LP, Dalcin KB, Souza DO. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol. 2004;24(1):123-8. [ Links ]
55. Anderson CM, Swanson RA. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia. 2000;32(1):1-14. [ Links ]
56. Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001;65(1):1-105. [ Links ]
57. Mathew SJ, Coplan JD, Schoepp DD, Smith EL, Rosenblum LA, Gorman JM. Glutamate-hypothalamic-pituitary-adrenal axis interactions: implications for mood and anxiety disorders. CNS Spectr. 2001;6(7):555-6, 561-4. [ Links ]
58. Borges K, Dingledine R. AMPA receptors: molecular and functional diversity. Prog Brain Res. 1998;116:153-70. [ Links ]
59. Bleakman D, Lodge D. Neuropharmacology of AMPA and kainate receptors. Neuropharmacology. 1998;37(10-11):1187-204. [ Links ]
60. Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol. 2001;21(5):484-7. [ Links ]
61. Li X, Tizzano JP, Griffey K, Clay M, Lindstrom T, Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology. 2001;40(8):1028-33. [ Links ]
62. Knapp RJ, Goldenberg R, Shuck C, Cecil A, Watkins J, Miller C, et al. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol. 2002;440(1):27-35. [ Links ]
63. Martinez-Turrillas R, Frechilla D, Del Rio J. Chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus. Neuropharmacology. 2002;43(8):1230-7. [ Links ]
64. Svenningsson P, Tzavara ET, Witkin JM, Fienberg AA, Nomikos GG, Greengard P. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci USA. 2002;99(5):3182-7. [ Links ]
65. Skolnick P, Legutko B, Li X, Bymaster FP. Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol Res. 2001;43(5):411-23. [ Links ]
66. Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci. 2000;20(1):8-21. [ Links ]
67. Zafra F, Hengerer B, Leibrock J, Thoenen H, Lindholm D. Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors. EMBO J. 1990;9(11):3545-50. [ Links ]
68. Hayashi T, Umemori H, Mishina M, Yamamoto T. The AMPA receptor interacts with and signals through the protein tyrosine kinase LYN. Nature. 1999;397(6714):72-6. [ Links ]
69. Legutko B, Li X, Skolnick P. Regulation of BDNF expression in primary neuron culture by LY3922098, a novel AMPA receptor potentiator. Neuropharmacology. 2001;40(8):1019-27. [ Links ]
70. Bai F, Bergeron M, Nelson DL. Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology. 2003;44(8):1013-21. [ Links ]
71. O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES. AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets CNS Neurol Disord. 2004;3(3):181-94. [ Links ]
72. Dimond SJ, Scammell RE, Pryce IG, Huws D, Gray C. Some effects of piracetam (UCB 6215, Nootropyl) on chronic schizophrenia. Psychopharmacology (Berl). 1979;64(3):341-8. [ Links ]
73. Oepen G, Eisele K, Thoden U, Birg W. Piracetam improves visuomotor and cognitive deficits in early Parkinsonisma pilot study. Pharmacopsychiatry. 1985;18(6):343-6. [ Links ]
74. Ingvar M, Ambros-Ingerson J, Davis M, Granger R, Kessler M, Rogers GA, et al. Enhancement by an ampakine of memory encoding in humans. Exp Neurol. 1997:146(2):553-9. [ Links ]
Mount Sinai School of Medicine
One Gustave L. Levy Place, Box 1218
10029 New York, NY
Phone: (212) 241-4480 Fax: (212) 824-2302
Financing: NIMH Career Development Award K23MH069656
Conflict of interests: None
Submitted: 8 July 2005
Accepted: 15 July 2005